Physician profile
Michael Bornemann
NPI 1184622920
$13,507.61
in general payments reported to CMS, 2019-2025
28 companies · $1,894 in 2025
The $1,894 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,027 · 2020: $1,464 · 2021: $1,476 · 2022: $2,478 · 2023: $2,231 · 2024: $1,938 · 2025: $1,894.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,581 · Education: $422 · Gift: $59.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,580.94 |
| Education | $421.99 |
| Gift | $59.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,614.50 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,620.33 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $1,401.57 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $1,052.85 | 2019-2022 | |
| Radius Health, INC. | $950.84 | 2019-2025 | Tymlos |
| Amgen INC. | $901.59 | 2019-2025 | Tepezza, Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $798.94 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Dexcom, INC. | $709.14 | 2022-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $626.79 | 2022-2025 | |
| Insulet Corporation | $598.45 | 2019-2025 | Omnipod |
| Mannkind Corporation | $449.37 | 2021-2025 | Afrezza |
| Merck Sharp & Dohme LLC | $336.63 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $239.46 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $206.95 | 2022-2025 | Strensiq |
| Abbott Laboratories | $205.26 | 2022-2025 | Freestyle Libre 3 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $147.66 | 2019-2024 | |
| Corcept Therapeutics | $140.95 | 2021-2025 | Korlym |
| Horizon Therapeutics Plc | $116.99 | 2022-2023 | Tepezza |
| Medtronic, INC. | $107.63 | 2022-2024 | Inpen Smart Insulin Delivery System, Minimed 780g |
| Chiesi USA, INC. | $48.69 | 2025 | Mycapssa, Myalept |
| Neurocrine Biosciences, INC. | $45.16 | 2025 | |
| Xeris Pharmaceuticals, INC. | $43.15 | 2024-2025 | Gvoke Hypopen |
| Amryt Pharma Holdings LTD | $29.28 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $26.36 | 2022 | |
| Amarin Pharma, INC. | $24.94 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $21.92 | 2019 | |
| Kyowa Kirin, INC. | $21.50 | 2023 | |
| Medtronic Minimed, INC. | $20.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Bornemann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.